Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. (Q38519252)

From Wikidata

Jump to navigation Jump to search

scientific article published on 04 June 2015

Language	Label	Description	Also known as
English	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	scientific article published on 04 June 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

based on heuristic

inferred from title

James Chih-Hsin Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Lecia V Sequist

2

object named as

Lecia V Sequist

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Sarayut Lucien Geater

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Chun-Ming Tsai

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Martin Schuler

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nobuyuki Yamamoto

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sai-Hong I Ou

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Daniel Massey

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Victoria Zazulina

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Yi-Long Wu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

4 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

830-838

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00026-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38519252&oldid=1535232357"